PHIO
What one share of Phio Pharmaceuticals holds
Pharmaceutical Preparations
Phio Pharmaceuticals Corp. (“Phio,” “we,” “our” or the “Company”) is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells.
Phio Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.36 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.28 |
| Cash and investments | $1.12 |
| Book value | $1.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$16.41 | $0.01 | −$11.51 | — | $8.35 |
| 2017 | — | −$5.52 | $0.09 | −$4.30 | — | $0.75 |
| 2018 | $1.08 | −$57.46 | $0.04 | −$58.75 | — | — |
| 2019 | $0.05 | −$19.33 | $0.16 | −$18.92 | — | $8.59 |
| 2020 | $0.00 | −$1.92 | $0.00 | −$1.92 | — | $2.25 |
| 2021 | — | −$12.43 | $0.05 | −$11.14 | — | $19.44 |
| 2022 | — | −$10.10 | $0.11 | −$10.78 | — | $9.52 |
| 2023 | — | −$46.76 | $0.02 | −$46.45 | — | $18.57 |
| 2024 | — | −$9.08 | $0.00 | −$9.03 | — | — |
| 2025 | — | −$1.45 | $0.00 | −$1.34 | — | $1.73 |